This allows them to selectively kill cancer cells, overcome resistance, reduce toxicity to healthy tissues, and expand treatment options for difficult subtypes like HER2-low and triple-negative breast cancer. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.